CALGB 10403 is a landmark clinical study that tested whether a pediatric-style chemotherapy regimen could be safely and effectively applied to older adolescents and young adults (AYA)—typically aged 17–39, and even up to 40—with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL)
Contact Us
Thank you for visiting 3J Pharma Inc – Interactive Medical Corner. Please use the form below for general inquiries, collaborations, or website feedback.
Important: This form is not for patient-specific medical advice or emergency communication. Always consult your healthcare provider directly for clinical concerns.
SUBSCRIBE TO OUR NEWSLETTER
Error: Your Requested widget "Blog Subscriptions (Jetpack) " is not in the widget list.